ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0858

Baricitinib in Early Polymyalgia Rheumatica (BACHELOR Study)

Alain SARAUX1, Guillermo CARVAJAL ALEGRIA2, Emmanuelle Dernis3, christian roux4, Christophe Richez5, Alice TISON6, Baptiste Quere7, Sandrine Jousse-Joulin8, Dewi Guellec7, Thierry Marhadou9, Patrice Kervarrec7, Divi Cornec10, Catherine Le Henaff7, Sandra Lesven7, nowak emmanuel7, Aghiles Souki7 and Valerie Devauchelle11, 1CHU Brest, Brest, France, 2CHRU de Tours, Tours, France, 3CH LE MANS, LE MANS, Pays de la Loire, France, 4rheumatology department, university Cote d'Azur, nice, France, 5Université de Bordeaux, Bordeaux, France, 6CHU de la Cavale Blanche, Brest, France, Brest, France, 7Centre Hospitalier Regional Universitaire (CHU) de Brest, Brest, France, 8cavale blanche hospital, brest, France, 9CHU Cavale Blanche, Brest, France, 10University of Brest, Brest, France, 11UBO, Brest, France

Meeting: ACR Convergence 2024

Keywords: Biologicals, geriatrics, glucocorticoids, Polymyalgia Rheumatica (PMR), Randomized Trial

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases I

Session Type: Abstract Session

Session Time: 3:00PM-4:30PM

Background/Purpose: Moderate glucocorticoids (GCs) improve nearly all cases of polymyalgia rheumatica (PMR) but related adverse events are common in senior patients.  The purpose of this randomized placebo-controlled trial in early PMR was to evaluate whether baricitinib (JAK 1/2 inhibitor) allows to reach disease control without GCs in recent-onset PMR. Moderate glucocorticoids (GCs) improve nearly all cases of polymyalgia rheumatica (PMR) but related adverse events are common in senior patients. The purpose of this randomized placebo-controlled trial in early PMR was to evaluate whether baricitinib (JAK 1/2 inhibitor) allows to reach disease control without GCs in recent-onset PMR.

Methods: We conducted a double-blind randomized (1:1) placebo-controlled parallel-group trial between December 1, 2020, and August 30, 2023. Thirty-four patients with recent (< 6 months) naïve to GCs PMR with C Reactive PMR activity score (CRP PMR-AS) >17 received oral baricitinib 4 mg or matching placebo, with oral GCs rescue in cases of high disease activity for 12 weeks, and then baricitinib 2 mg or matching placebo, until week 24. Subdeltoid GC injection at W0 and W4 as permitted. The primary endpoint was the CRP PMR-AS≤10 without oral GCs rescue from W0 to week 12.

Results: We randomized 34 patients (18 baricitinib and 16 placebo) (Figure 1). The primary endpoint was reached at week 12 by 14/18 (77.8%) and 2/16 (13.3%) of patients in the baricitinib and placebo groups, respectively (RR (95% CI): 5.8 (3.2; 10.6); crude p value=0.0004; adjusted p value< 0.0001) (Figure 2). Among secondary outcomes assessed at week 12 erythrocyte sedimentation rate (ESR) PMR-AS, ESR and visual analogic score pain were significantly lower in the placebo group than in the baricitinib group (p=0.02, 0.02 and 0.03 respectively) but patients of the placebo group received more GCs and patients of the baricitinib group had a higher MCS SF36 and EQ5D (p=0.005 and 0.043, respectively). There was no flare until week 36. There was no death, no major adverse cardiovascular events or safety signal.

Conclusion: This study suggests that baricitinib alone 4 mg 12 weeks and then 2 mg 12 weeks allows sustained low disease activity 36 weeks in early PMR patients without safety signal.

Supporting image 1

Figure 1 (Flowchart)

Supporting image 2

Figure 2 (Results)


Disclosures: A. SARAUX: Abbvie, BMS, Galapagos, Lilly, Novartis, Nordic, Pfizer, Roche-Chugai, Sanofi, UCB, 6, Abbvie, Bms, Lilly, Novartis, 5; G. CARVAJAL ALEGRIA: Abbvie, Chugai, Lilly, Novartis, 6; E. Dernis: AbbVie/Abbott, 2, Amgen, 2, Boehringer-Ingelheim, 2, Celgene, 2, Eli Lilly, 2, Galapagos, 2, Gilead, 2, Janssen, 2, Merck/MSD, 2, Nordic Pharma, 2, Novartis, 2, Pfizer, 2, Roche, 2, roche-chugaï, 2, Sandoz, 2, Sanofi, 2, UCB, 2; c. roux: None; C. Richez: Abbvie, Astra Zeneca, BMS, GSK, Lilly, Novartis, Pfizer, UCB, 6, Lilly and Biogen, 5; A. TISON: Galapagos, BMS, 6; B. Quere: None; S. Jousse-Joulin: None; D. Guellec: Lilly, Janssen-Cilag, Glaxosmithkline, 6; T. Marhadou: Abbvie, Amgen, Chugaï, Lilly, Mylan, Novartis, Pfizer, 6; P. Kervarrec: None; D. Cornec: None; C. Le Henaff: None; S. Lesven: None; n. emmanuel: None; A. Souki: None; V. Devauchelle: AbbVie, 2, BMS, 2, 5, Chugai, 5, Galapagos, 2, Janssen, 2, Lilly, 2, 5, Novartis, 2, Pfizer, 2.

To cite this abstract in AMA style:

SARAUX A, CARVAJAL ALEGRIA G, Dernis E, roux c, Richez C, TISON A, Quere B, Jousse-Joulin S, Guellec D, Marhadou T, Kervarrec P, Cornec D, Le Henaff C, Lesven S, emmanuel n, Souki A, Devauchelle V. Baricitinib in Early Polymyalgia Rheumatica (BACHELOR Study) [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/baricitinib-in-early-polymyalgia-rheumatica-bachelor-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/baricitinib-in-early-polymyalgia-rheumatica-bachelor-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology